Результаты поиска

Chinese expert consensus recommendations for the administration of immune checkpoint inhibitors to special cancer patient populations.

Immune checkpoint inhibitors (ICIs) targeting programmed cell death 1, programmed cell death ligand 1, and cytotoxic T lymphocyte-associated antigen-4 have shown significantly durable clinical benefits and tolerable toxicities and have improved the survival of patients with various types of cancer. Since 2018, the National Medical Products Administration of China has approved 17 ICIs as the standard treatment for certain advanced or metastatic solid tumors. As ICIs represent a broad-spectrum antitumor strategy, the populations eligible for cancer immunotherapy are rapidly expanding. However, t

Совпадение в полном тексте источника
… autoimmune CD4 + or CD8 + T cells differentiated from immature CD4 + CD8 + T cells. 65 Studies have shown that positive peripheral blood acetylcholine receptor autoantibodies, decreased B cells and Tregs, and increased T-cell receptor diversity in peripheral blood mononuclear cells are associated with polymyositis …

Chest and Mediastinum

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Autoimmune Diseases and Plasma Cells Dyscrasias: Pathogenetic, Molecular and Prognostic Correlations.

Multiple myeloma and monoclonal gammopathy of undetermined significance are plasma cell dyscrasias characterized by monoclonal proliferation of pathological plasma cells with uncontrolled production of immunoglobulins. Autoimmune pathologies are conditions in which T and B lymphocytes develop a tendency to activate towards self-antigens in the absence of exogenous triggers. The aim of our review is to show the possible correlations between the two pathological aspects. Molecular studies have shown how different cytokines that either cause inflammation or control the immune system play a part i

Совпадение в полном тексте источника
… Additionally, cases of polymyositis, Graves’ illness, optic neuritis and vasculitis were noted, and thyroid problems have been reported to occur in up to 6% of patients receiving lenalidomide therapy in the past [ 131 ]. …

Novel and potential future therapeutic options in systemic autoimmune diseases.

Autoimmune inflammation is caused by the loss of tolerance to specific self-antigens and can result in organ-specific or systemic disorders. Systemic autoimmune diseases affect a significant portion of the population with an increasing rate of incidence, which means that is essential to have effective therapies to control these chronic disorders. Unfortunately, several patients with systemic autoimmune diseases do not respond at all or just partially respond to available conventional synthetic disease-modifying antirheumatic drugs and targeted therapies. However, during the past few years, som

Совпадение в полном тексте источника
… Potential future therapeutic options of autoimmune myositis The group of idiopathic inflammatory myopathies consists of heterogeneous disorders, such as polymyositis, dermatomyositis, antisynthetase syndrome, immune-mediated necrotizing myopathy, inclusion body myositis, and overlap myositis syndromes …

Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… alternative donors (cord blood, haploidentical and mismatched unrelated donors), MP-CMML myeloproliferative CMML, MRD minimal residual disease, MS multiple sclerosis, MSD matched sibling donor, MUD well-matched unrelated donor (8/8, 10/10, or 9/10 if mismatched is in DQB1), NA not applicable, PM-DM polymyositis-dermatomyositis … carefully selected subpopulations of patients with juvenile inflammatory arthritis (e.g., polyarticular course or onset, inadequate response and/or intolerance to prednisone or disease-modifying antirheumatic drugs) and other ADs including systemic sclerosis, systemic lupus erythematosus, vasculitis and polymyositis-dermatomyositis …

I

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… They can be subdivided into primary idiopathic polymyositis (PM), primary idiopathic dermatomyositis (DM), PM–DM in childhood, myositis associated with malignancy and myositis combined with other systemic rheumatic disorders (such as scleroderma, systemic lupus erythematosus, Sjögren’s syndrome or rheumatoid …

Терапевтическое применение иммунобиологии в аутоиммунных и воспаленных заболеваниях.

Иммунобиологика или биологическая экспертиза революционизировали терапевтическую парадигму аутоиммунных и подстрекательских заболеваний путем выборочного целеопределения и модуляции дисрегулированных иммунных путей. По сравнению с обычными широкоспектральными иммунопрепрессантами биологика обеспечивает более конкретный и основанный на механизмах рациональный подход, зачастую связанный с повышением эффективности и сокращением неблагоприятных явлений. В этом обзоре содержится всеобъемлющий обзор репертуара терапевтической биологики, механизмов их действий, важнейших клинических испытаний и клини

Совпадение в полном тексте источника
… Clinical and preclinical data further support its benefit in idiopathic inflammatory myopathies (IIMs) such as polymyositis, dermatomyositis, and inclusion body myositis [ 62 ]. …

Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations.

For over two decades, the EBMT has updated recommendations on indications for haematopoietic cell transplantation (HCT) practice based on clinical and scientific developments in the field. This is the ninth special EBMT report on indications for HCT for haematological diseases, solid tumours and immune disorders. Our aim is to provide guidance on HCT indications according to prevailing clinical practice in EBMT countries and centres. In order to inform patient decisions, these recommendations must be considered with the risk of the disease, risk of HCT procedure and non-HCT strategies, includi

Совпадение в полном тексте источника
… , haploidentical and mismatched unrelated donors), MP-CMML myeloproliferative CMML, MRD measurable residual disease, MS multiple sclerosis, MSD matched sibling donor, MUD well-matched unrelated donor (8/8, 10/10, or 9/10 if mismatched is in DQB1), MYSEC-PM for secondary MF, NA not applicable, PM-DM polymyositis-dermatomyositis … Auto-HCT may be considered for carefully selected subpopulations of patients with juvenile inflammatory arthritis (e.g. polyarticular or systemic course or onset, inadequate response and/or intolerance to prednisone or disease-modifying antirheumatic drugs) and other ADs including SSc, SLE, vasculitis and polymyositis-dermatomyositis …

Onco-Cardiology: Consensus Paper of the German Cardiac Society, the German Society for Pediatric Cardiology and Congenital Heart Defects and the German Society for Hematology and Medical Oncology.

The acute and long-lasting side effects of modern multimodal tumour therapy significantly impair quality of life and survival of patients afflicted with malignancies. The key components of this therapy include radiotherapy, conventional chemotherapy, immunotherapy and targeted therapies. In addition to established tumour therapy strategies, up to 30 new therapies are approved each year with only incompletely characterised side effects. This consensus paper discusses the risk factors that contribute to the development of a potentially adverse reaction to tumour therapy and, in addition, defines

Совпадение в полном тексте источника
… Progressive hypoventilation due to mixed CD8(+) and CD4(+) lymphocytic polymyositis following tremelimumab–durvalumab treatment. J Immunother Cancer. 2017;5:54. doi: 10.1186/s40425-017-0258-x. 64. Johnson DB, Balko JM, Compton ML, et al. …

How does academia respond to the burden of infectious and parasitic disease?

BackgroundAcademic research is one of the main avenues through which humans can fight the threat of infectious diseases. However, there have been concerns regarding whether the academic system has provided sufficient efforts to fight infectious diseases we potentially face. Answering these questions could contribute to evidence-based recommendations for setting research priorities and third-mission policies.MethodsWith a focus on one of the most common categories of communicable diseases, infectious and parasitic diseases (IPDs), we searched Web of Science for articles and reviews relevant to

Совпадение в полном тексте источника
… Musculoskeletal disease" OR "Musculoskeletal disorder" OR “Musculoskeletal pain” OR "Arthropathy" OR "Dermatomyositis" OR "Eosinophilia myalgia syndrome"OR "Fibromyalgia"OR "Myositis ossificans" OR "Osteoarthrosis" OR "Osteochondritis" OR "Osteomyelitis" OR "Osteoporosis" OR "Polymyalgia rheumatica" OR "Polymyositis …

Inflammaging, an Imbalanced Immune Response That Needs to Be Restored for Cancer Prevention and Treatment in the Elderly.

Nowadays, new advances in society and health have brought an increased life expectancy. However, at the same time, aging comes with complications that impact the development of autoimmunity, neurodegenerative diseases and cancer. These complications affect the quality of life and impact the public health system. Specifically, with aging, a low-grade chronic sterile systemic inflammation with self-reactivity in the absence of acute infection occurs termed inflammaging. Inflammaging is related to an imbalanced immune response that can be either naturally acquired with aging or accelerated due to

Совпадение в полном тексте источника
… Specifically, cancer risk was increased in DMM and polymyositis but not in sporadic inclusion body myositis. Moreover, ovarian cancer was more prevalent in DMM than in the general population [ 161 ]. …

Glucocorticoid-induced osteonecrosis in systemic lupus erythematosus patients.

Osteonecrosis (ON) is a complex and multifactorial complication of systemic lupus erythematosus (SLE). ON is a devastating condition that causes severe pain and compromises the quality of life. The prevalence of ON in SLE patients is variable, ranging from 1.7% to 52%. However, the pathophysiology and risk factors for ON in patients with SLE have not yet been fully determined. Several mechanisms for SLE patients' propensity to develop ON have been proposed. Glucocorticoid is a widely used therapeutic option for SLE patients and high-dose glucocorticoid therapy in SLE patients is strongly assoc

Совпадение в полном тексте источника
… TABLE 2 Prevalence of osteonecrosis in rheumatic diseases Underlying diseases | Prevalence (%) Systemic lupus erythematosus | 1.7‐52 Rheumatoid arthritis | 0.4‐4.8 Polymyositis/dermatomyositis | 0.1‐4.9 Granulomatosis with polyangiitis | 3.7 Polymyalgia rheumatica | 3.3 Mixed connective tissue disease …

Ход работы 34th Симпозиум ESVN-ECVN 23rd-24th сентябрь 2022.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Research progress on the clinical application and mechanism of iguratimod in the treatment of autoimmune diseases and rheumatic diseases.

Autoimmune diseases are affected by complex pathophysiology involving multiple cell types, cytokines, antibodies and mimicking factors. Different drugs are used to improve these autoimmune responses, including nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, antibodies, and small molecule drugs (DMARDs), which are prevalent clinically in the treatment of rheumatoid arthritis (RA), etc. However, low cost-effectiveness, reduced efficacy, adverse effects, and patient non-response are unattractive factors driving the development of new drugs such as iguratimod. As a new disease-modi

Совпадение в полном тексте источника
… About one-fifth of patients, the typical lesions of connective tissue diseases are later than connective tissue disease-related interstitial lung diseases, and the lung manifestations are years or months, especially rheumatoid arthritis, dermatomyositis, polymyositis, and systemic lupus erythematosus …

Skeletal muscle dysfunction induced by cancer immunotherapy: mechanistics insights and surgical implications.

Cancer immunotherapy has revolutionized cancer treatment, yet its effects extend far beyond tumor eradication. Accumulating evidence indicates that immunotherapy-associated skeletal muscle dysfunction represents a complex, cross-organ pathological process driven by dynamic crosstalk between the tumor microenvironment and peripheral tissues. Rather than an isolated adverse event, muscle injury emerges from integrated mechanisms including inflammatory cytokine spillover, aberrant immune cell infiltration, metabolic reprogramming, vascular dysfunction, and impaired regenerative signaling. Central

Совпадение в полном тексте источника
… In clinical and research settings, SWE can be used to monitor immune-mediated myopathies, including polymyositis and cancer therapy-related myopathies. …

Passive Monoclonal and Polyclonal Antibody Therapies

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Ход работы сессии 29th Европейский конгресс педиатрии.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Abstracts - IANCON 2025

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Current State of Knowledge on Primary Sjögren's Syndrome, an Autoimmune Exocrinopathy.

Primary Sjögren's syndrome (pSS) is a chronic systemic autoimmune rheumatic disease characterized by lymphoplasmacytic infiltration of the salivary and lacrimal glands, whereby sicca syndrome and/or systemic manifestations are the clinical hallmarks, associated with a particular autoantibody profile. pSS is the most frequent connective tissue disease after rheumatoid arthritis, affecting 0.3-3% of the population. Women are more prone to develop pSS than men, with a sex ratio of 9:1. Considered in the past as innocent collateral passive victims of autoimmunity, the epithelial cells of the saliv

Proceedings 27th Symposium ESVN‐ECVN

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.